Escherichia coli, J&J and Sanofi

Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds.
J&J, Sanofi stop E.coli vaccine trial due to low effectiveness
Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies said on Thursday.
J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.
Sanofi, J&J abandon trial of E coli vaccine after poor data
Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.
Sanofi takes $250M hit after gamble on J&J E. coli vaccine ends in phase 3 failure
A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, the asset has failed its phase 3 trial. | A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E.
Sanofi to take $250M charge on study failure for E. coli vaccine
The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.”
J&J to Discontinue E.coli Vaccine Candidate Study
Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi. The drugmaker said its decision was based on the recommendation of an independent committee that found the vaccine candidate may not be sufficiently effective compared with a placebo in preventing infections caused by a group of bacteria commonly found in the gut.
Sanofi Ends E.coli Vaccine Trial Amid Efficacy Concerns
Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its
Sanofi and J&J discontinue late stage trial of their experimental E.coli vaccine
Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The vaccine for extraintestinal pathogenic E.
Expert: E. coli infection among doctors at Hong Kong hospital ‘unlikely to spread widely’
An E coli infection linked to the death of a doctor in Princess Margaret Hospital is unlikely to lead to widespread ...
Hong Kong doctor killed by suspected E coli infection hailed as ‘good role model’
The deceased doctor who was part of a suspected Shiga toxin-producing E coli cluster at a Hong Kong public hospital has been ...
RTHK News3d
Doctor dies in suspected E. coli outbreak
Health officials on Tuesday confirmed that an oncologist at Princess Margaret Hospital died last Friday of a suspected E.
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn’t demonstrate sufficient ...
WATTPoultry.com2d
Enterococcus coinfection makes E. coli more deadly in poultry
The avian specific form of E. coli can lead to an infection called colibacillosis that can cause septicemia, organ failure and death.
Tackling the threat of drug-resistant E. coli in China
A comprehensive seven-year study across 20 Chinese provinces has revealed a concerning rise in antimicrobial resistance (AMR) ...